InterVenn is developing a first-in-class mass spec-based glycoproteomic clinical diagnostic test for ovarian cancer.
Currently undergoing clinical validation in a global, multi-center clinical trial, this proprietary test will enable clinicians to distinguish benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test.
The purpose of this study is to evaluate the clinical performance of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL) test by collecting and storing biological samples (blood) and characterizing protein biomarkers in serum of cancer versus non-cancer patients.
The VOCAL study is for adult women who present with a known adnexal (pelvic) mass discovered by an imaging test, such as an ultrasound or CT scan.
A total of 1,200 subjects from various parts of the world will be participating in this study.
For more information, please email ovarian@venn.bio or visit clinicaltrials.gov
The risks to participation are very small. Participation in the VOCAL study involves a simple blood draw prior to any surgery and the collection of your clinical data.
For more information, please email ovarian@venn.bio or visit clinicaltrials.gov
There is no direct benefit to the participants of this research study. The benefit goes to research and the development of a diagnostic profile for ovarian cancer.
The study doctor and research team will review all of the details of the clinical study in further detail. You will also be given an informed consent document, which will include a complete overview of the study.
The study is being conducted in multiple locations throughout the United States, Australia, the Philippines and Malaysia.
To locate contact information for a clinical site, go to ovarian@venn.bio or visit clinicaltrials.gov or contact ovarian@venn.bio
If local to the Philippines, please visit Health Research
